Rational vaccinology with spherical nucleic acids.

Area of Science:

• Nanotechnology
• Immunology
• Oncology

Background:

• Nanostructures can deliver antigens and adjuvants for cancer immunotherapy.
• Spherical nucleic acids (SNAs) are an emerging class of nanotherapeutic materials with potential in cancer vaccines.

Purpose of the Study:

• To investigate the efficacy of SNAs in delivering peptide antigens and nucleic acid adjuvants for cancer immunotherapy.
• To evaluate the impact of SNA structure on immune response and antitumor activity in mouse models.

Main Methods:

• Utilized three compositionally similar but structurally distinct SNA structures.
• Administered SNA-based vaccines in three established mouse tumor models.
• Assessed CD8+ T cell cross-priming, tumor growth, survival rates, and immunological memory.

Main Results:

• SNA structure significantly influenced T cell priming and antitumor immune responses.
• The most effective SNA structure synchronized antigen presentation and costimulatory marker expression.
• Vaccination with the optimal SNA structure led to improved survival, complete tumor elimination in 30% of mice, and protective memory in a human papillomavirus-associated cancer model.

Conclusions:

• SNA nanostructures offer a modular platform for rational cancer vaccine design.
• Antitumor effects are dependent on antigen incorporation method, highlighting design flexibility.
• SNAs can elicit robust and durable antitumor immunity, including immunological memory.